Abstract: A method may include training, based at least on a first data, a machine learning model to perform one or more natural language processing tasks. The trained machine learning model may be deployed to a production environment to support natural language based interactions with a digital assistant. A plurality of performance metrics may be generated to include explanation data associated with the deployed machine learning model operating on a second data as well as one or more data characteristics of the second data such as data drift, data bias, and outliers. A user interface may be generated to display, at a client device, a visual representation of at least a portion of the plurality of performance metrics associated with the deployed machine learning model. Related methods and computer program products are also disclosed.

Abstract: Infrastructure for zero trust network access (ZTNA) is deployed as a cloud-based service remotely from a customer premises where user applications are hosted. By connecting an appliance on the customer premises to the cloud-based service through a secure tunnel or the like, an application hosted on the customer premises can then be accessed externally as a ZTNA application without the customer premises opening a firewall to public networks or otherwise exposing potential attack surfaces to the customer premises.

Abstract: The present disclosure relates to a process for the preparation of ethyl tert-butyl ether comprising: (a) reacting ethanol with a mixture of C4 hydrocarbon feed in the presence of a catalyst to obtain a mixture; and (b) contacting the mixture with an entrainer at a temperature in the range of 40-70° C. and a pressure in the range of 15-30 bars to obtain ethyl tert-butyl ether, wherein, the mixture of C4 hydrocarbon feed comprises isobutylene, and the ethanol to isobutylene mole ratio is in the range of 1:1 to 2:1. The present disclosure also discloses a process of separating ethanol and ethyl tert-butyl ether. Further, the present disclosure discloses a composition comprising ethyl tert-butyl ether with a purity in the range of 91%-93%.

Abstract: A method for exposing artificial intelligence content as a cloud service may include onboarding, by a service broker of a core platform hosting an artificial intelligence (AI) resource, a service provider tenant providing the artificial intelligence resource. The onboarding of the first service provider tenant includes creating, at the core platform, a function specific service broker associated with the artificial intelligence resource. The function specific service broker may then onboard one or more service consumer tenants for accessing the artificial intelligence resource associated with the first provider tenant. Moreover, in response to the one or more service consumer tenants accessing the artificial intelligence resource, the function specific service broker may authenticate the one or more service consumer tenants and meter a usage of the artificial intelligence resource by the one or more service consumer tenants. Related methods and computer program products are also disclosed.

Abstract: An improved information management system that implements a staging area or cache to temporarily store primary data in a native format before the primary data is converted into secondary copies in a secondary format is described herein. For example, the improved information management system can include various media agents that each include one or more high speed drives. When a client computing device provides primary data for conversion into secondary copies, the primary data can initially be stored in the native format in the high speed drive(s). If the client computing device then submits a request for the primary data, the media agent can simply retrieve the primary data from the high speed drive(s) and transmit the primary data to the client computing device. Because the primary data is already in the native format, no conversion operations are performed by the media agent, thereby reducing the restore delay.

Abstract: Disclosed are compounds of Formula (I) or salts thereof, wherein Ring Het, R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Abstract: An AI platform mesh includes a machine learning control plane hosted in a container orchestration cluster. The machine learning control plane includes a worker plane manager and a set of machine learning services. One or more remote runtime environments configured to execute machine learning workloads can be registered with the machine learning control plane via the worker plane manager. The remote runtime environments can communicate with the set of machine learning services via the worker plane manager.

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Abstract: The present invention relates to a pharmaceutical composition comprising N-(4-(6,7-dimethoxy quinolin-4-yloxy)phenyl)-N?-(4-fluoro phenyl) cyclopropane-1,1-dicarboxamide, (2S)-hydroxy butanedioate of formula-1 and a pharmaceutically acceptable carrier wherein the said pharmaceutical composition has a dimer impurity of formula-2 less than about 2.0% as measured by HPLC.

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Abstract: An improved information management system that implements a staging area or cache to temporarily store primary data in a native format before the primary data is converted into secondary copies in a secondary format is described herein. For example, the improved information management system can include various media agents that each include one or more high speed drives. When a client computing device provides primary data for conversion into secondary copies, the primary data can initially be stored in the native format in the high speed drive(s). If the client computing device then submits a request for the primary data, the media agent can simply retrieve the primary data from the high speed drive(s) and transmit the primary data to the client computing device. Because the primary data is already in the native format, no conversion operations are performed by the media agent, thereby reducing the restore delay.

Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, and R5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Abstract: Disclosed are compounds of Formula (I) or salts thereof, wherein Ring Het, R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Abstract: The present disclosure provides a process for preparation of 3,6-dichlorocyano pyrazine, 3,6-dioxopiperizine derivatives and production of favipiravir via ammonia or amine-mediated cyclization and chlorination using POCl3 in the presence of pyridine or PCl5. [Formula] wherein in 3,6-dioxopiperazine derivatives (III), X is CN, CONH2 or COOR2?, R1, R2 and R2? are individually selected from H, C1-C12 alkyl, COOR3 and SO2R3 wherein R3 is substituted or unsubstituted linear or branched lower alkyl.

Abstract: Protecting PII submitted through a browser. In some embodiments, a method may include detecting multiple PII of a user submitted to multiple organization websites through a browser. The method may also include encrypting each of the PII. The method may further include storing each of the encrypted PII along with an identifier of the organization website to which the PII was submitted. The method may also include receiving a request to view the PII along with an indicator of the organization website to which the PII was submitted. The method may further include retrieving each of the encrypted PII along with the identifier of the organization website to which the PII was submitted. The method may also include decrypting each of the encrypted PII. The method may further include displaying each of the PII along with the indicator of the organization website to which the PII was submitted.

Abstract: Disclosed are compounds of Formula (I) or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Abstract: An improved information management system that implements a staging area or cache to temporarily store primary data in a native format before the primary data is converted into secondary copies in a secondary format is described herein. For example, the improved information management system can include various media agents that each include one or more high speed drives. When a client computing device provides primary data for conversion into secondary copies, the primary data can initially be stored in the native format in the high speed drive(s). If the client computing device then submits a request for the primary data, the media agent can simply retrieve the primary data from the high speed drive(s) and transmit the primary data to the client computing device. Because the primary data is already in the native format, no conversion operations are performed by the media agent, thereby reducing the restore delay.

Abstract: Techniques for providing shared access to, e.g., a small computer system interface (SCSI) storage device in a computer network include providing an operational mode on SCSI interfaces with a first media agent and a second media agent such that, in response to inquiry messages on the SCSI interfaces, the SCSI storage device appears as a SCSI target device to the first media agent and the second media agent and mapping data operations between the first media agent and the SCSI storage device and the second media agent and the SCSI storage device to logically unique channel numbers for the first media agent and the second media agent to perform data storage operations over their respective SCSI interfaces by concurrently sharing the SCSI storage device.

Abstract: Methods, systems, and computer-readable storage media for providing a DLS-enriched view on data stored in a database system, the DLS-enriched view including a set of annotations indicating at least one application table and at least one field of the application table, storing a staging table corresponding to the application table field and a database trigger that is configured to write data from the field to the staging table in response to a change in the at least one application table, providing at least one IR artifact based on the DLS-enriched view, generating at least one DLS-specific entity and chaincode based on the IR artifact and a configuration for a DLS, to which the chaincode is to be deployed, deploying the chaincode to the DLS, and monitoring the one or more staging tables for changes and, in response to a change, recording data of the staging table to the DLS.

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.